ViiV Healthcare Announced FDA Approval for Cabenuva for Adults with HIV-1
From London we learned that ViiV Healthcare announced that the US Food and Drug Administration (FDA) approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults.

ViiV Healthcare is a global HIV company majority-owned by GlaxoSmithKline (This content is for paid subscribers.